Lantern Pharma CEO Panna Sharma Discusses Progress in AI-Driven Cancer Drug Development
Sep. 29, 2025
Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage biopharmaceutical company redefining
oncology drug development through artificial intelligence. Its proprietary RADR® platform leverages
over 200 billion oncology-specific data points to rapidly identify drug candidates, optimize patient
targeting, and de-risk clinical trials—cutting early development time and cost by up to 70% and 80%,
respectively. Lantern’s pipeline includes three clinical-stage assets: LP-300 (Phase 2) for NSCLC in
never-smokers, LP-184 (Phase 1) for DDR-deficient solid tumors, and LP-284 (Phase 1) for aggressive
B-cell lymphomas.
The company also advances CNS oncology programs via its subsidiary Starlight
Therapeutics and is developing novel antibody-drug conjugates (ADCs) in collaboration with global
partners. With 11 FDA designations, over 100 issued and pending patents, and partnerships spanning
Johns Hopkins, MD Anderson, and Bielefeld University, Lantern is positioned to unlock value through
precision-driven clinical execution and strategic collaborations—all backed by $19.7 million in cash and a lean operating structure.
Lantern Pharma is a client of RedChip. Visit LTRNinfo.com to learn more.
